India, May 22 -- Regeneron Pharmaceuticals Inc. (REGN), a biotechnology company, on Thursday released positive Phase 1/2 LINKER-AL2 results for Lynozyfic in the treatment of second line-plus systemic amyloid light chain (AL) amyloidosis.
Systemic AL amyloidosis is a rare hematological disorder wherein the body's clonal plasma cells produce light chain proteins that can clump together to form amyloid deposits in vital organs. The disease can be fatal, and there are no approved therapies following failure of standard-of-care treatments. Currently, first-line treatment involves a daratumumab-and-chemotherapy-containing quadruple combination, which shows a 53% hematologic complete response rate.
Lynozyfic is a full human, bispecific BCMAxCD3 ...